MBMichal Bista

Michal Bista

*This is an algorithmically generated author record based on publicly available information.

Michal Bista has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cover Feature: Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4 (ChemMedChem 7/2026)

    by Daria Kotlarek, Katarzyna Dudek, Bartosz Woźniak, Martyna W. Pastok, Dmitrii Shishov, Sylvain Cottens, Michał Biśta, Emilia Krzywiecka, Karolina M. Górecka‐Minakowska, Kinga Jurczak, et al.

  • Open Access

    Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4

    by Daria Kotlarek, Katarzyna Dudek, Bartosz Woźniak, Martyna W. Pastok, Dmitrii Shishov, Sylvain Cottens, Michał Biśta, Emilia Krzywiecka, Karolina M. Górecka‐Minakowska, Kinga Jurczak, et al.

    The application of targeted protein degradation is currently constrained by the limited availability of low‐molecular‐weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (von Hippel–Lindau ligase). In this study, we present the structure‐based drug design of high‐affinity ligands that engage E3 ligase GID4 (glucose‐induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis‐targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro, degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein–protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates.

  • Open Access

    A Robust Crystallographic Platform for High-Throughput β-Catenin Ligand Discovery

    by Marta Klejnot, Alicja N Skowron, Jaromir Szymański, Filip Ulatowski, Michał Biśta, Sylvain Cottens, Gabriela Dąbrowiecka, Daria Gajewska, Karolina M Górecka-Minakowska, Daria Kotlarek, et al.

    This study presents a robust crystallographic platform for assessing compounds binding to β-catenin. We developed a standardized protein production protocol for the armadillo domain of β-catenin (BC-ARM) and performed biophysical screens using Surface Plasmon Resonance (SPR) and Differential Scanning Fluorimetry (DSF). These findings led to the successful determination of the co-crystal structure of BC-ARM with compound 1 binding to previously reported site but distinct from known transcription factor binding sites. To broaden the search for novel BC binding sites, we utilized FragLites library with a cyclic peptide-stabilized BC-ARM construct. This yielded two high-resolution co-crystal structures identifying a previously unreported binding hotspot. Recognizing the limitations of the cyclic peptide-bound construct for general screening, we designed a novel, truncated BC-ARM construct. This new construct eliminates unstructured regions, reliably producing high-quality, diffracting crystals suitable for high-throughput crystallographic studies. In conclusion, the ligand-bound β-catenin structures and this novel, robust BC-ARM construct establish a powerful platform for further β-catenin investigation.

  • Open Access

    Ligand-induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4

    by Daria Kotlarek, Katarzyna Dudek, Bartosz Woźniak, Martyna W. Pastok, Dmitrii Shishov, Sylvain Cottens, Michał Biśta, Emilia Krzywiecka, Karolina M. Górecka-Minakowska, Kinga Jurczak, et al.

    The application of targeted protein degradation (TPD) is currently constrained by the limited availability of low-molecular-weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (Von Hippel-Lindau ligase). In this study, we present the structure-based drug design (SBDD) of high-affinity ligands that engage E3 ligase GID4 (Glucose-induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis-targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro , degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein-protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates. GRAPHICAL


  • Open Access

    Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1

    by Jakub Luptak, Michal Bista, David Fisher, Liz Flavell, Ning Gao, Kate Wickson, Steven L. Kazmirski, Tina Howard, Philip B. Rawlins, David Hargreaves

    Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) family, including Mcl-1 (myeloid cell leukaemia 1). This makes Mcl-1 a potential target for drug therapy, through which normal apoptosis may be restored by inhibiting the protective function of Mcl-1. Here, the discovery and biophysical properties of an anti-Mcl-1 antibody fragment are described and the utility of both the scFv and Fab are demonstrated in generating an Mcl-1 crystal system amenable to iterative structure-guided drug design.


  • Open Access

    Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

    by Joseph Shaw, Ian Dale, Paul Hemsley, Lindsey Leach, Nancy Dekki, Jonathan P. Orme, Verity Talbot, Ana J. Narvaez, Michal Bista, Daniel Martinez Molina, et al.


  • Open Access

    Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension

    by Teresa Collins, Kelly Gray, Michal Bista, Matt Skinner, Christopher Hardy, Haiyun Wang, Jerome T Mettetal, Alexander R Harmer

    Background and PurposeSeveral anti-angiogenic cancer drugs that inhibit VEGF receptor (VEGFR) signalling for efficacy are associated with a 15-60% incidence of hypertension. Tyrosine kinase inhibitors (TKIs) that have off-target activity at VEGFR-2 may also cause blood pressure elevation as an undesirable side effect. Therefore, the ability to translate VEGFR-2 off-target potency into blood pressure elevation would be useful in development of novel TKIs. Here, we have sought to quantify the relationship between VEGFR-2 inhibition and blood pressure elevation for a range of kinase inhibitors. Experimental ApproachPorcine aortic endothelial cells overexpressing VEGFR-2 (PAE) were used to determine IC50 for VEGFR-2 phosphorylation. These IC50 values were compared with published reports of exposure attained during clinical use and the corresponding incidence of all-grade hypertension. Unbound average plasma concentration (C-av,C-u) was selected to be the most appropriate pharmacokinetic parameter. The pharmacokinetic-pharmacodynamic (PKPD) relationship for blood pressure elevation was investigated for selected kinase inhibitors, using data derived either from clinical papers or from rat telemetry experiments. Key ResultsAll-grade hypertension was predominantly observed when the C-av,C-u was >0.1-fold of the VEGFR-2 (PAE) IC50. Furthermore, based on the PKPD analysis, an exposure-dependent blood pressure elevation >1mmHg was observed only when the C-av,C-u was >0.1-fold of the VEGFR-2 (PAE) IC50. Conclusions and ImplicationsTaken together, these data show that the risk of blood pressure elevation is proportional to the amount of VEGFR-2 inhibition, and a margin of >10-fold between VEGFR-2 IC50 and C-av,C-u appears to confer a minimal risk of hypertension.


  • Open Access

    Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease

    by Fernando Orden Rueda, Michal Bista, Matthew D. Newton, Anne U. Goeppert, M. Emanuela Cuomo, Euan Gordon, Felix Kröner, Jon A. Read, Jonathan D. Wrigley, David Rueda, et al.

    The CRISPR–Cas9 RNA-guided endonuclease system allows precise and efficient modification of complex genomes and is continuously developed to enhance specificity, alter targeting and add new functional moieties. However, one area yet to be explored is the base chemistry of the associated RNA molecules. Here we show the design and optimisation of hybrid DNA–RNA CRISPR and tracr molecules based on structure-guided approaches. Through careful mapping of the ribose requirements of Cas9, we develop hybrid versions possessing minimal RNA residues, which are sufficient to direct specific nuclease activity in vitro and in vivo with reduced off-target activity. We identify critical regions within these molecules that require ribose nucleotides and show a direct correlation between binding affinity/stability and cellular activity. This is the first demonstration of a non-RNA-guided Cas9 endonuclease and first step towards eliminating the ribose dependency of Cas9 to develop a XNA-programmable endonuclease.


  • Open Access

    MTH1 Substrate Recognition—An Example of Specific Promiscuity

    by J. Willem M. Nissink, Michal Bista, Jason Breed, Nikki Carter, Kevin Embrey, Jonathan Read, Jon J. Winter-Holt

    MTH1 (NUDT1) is an oncologic target involved in the prevention of DNA damage. We investigate the way MTH1 recognises its substrates and present substrate-bound structures of MTH1 for 8-oxo-dGTP and 8-oxo-rATP as examples of novel strong and weak binding substrate motifs. Investigation of a small set of purine-like fragments using 2D NMR resulted in identification of a fragment with weak potency. The protein-ligand X-Ray structure of this fragment provides insight into the role of water molecules in substrate selectivity. Wider fragment screening by NMR resulted in three new protein structures exhibiting alternative binding configurations to the key Asp-Asp recognition element of the protein. These inhibitor binding modes demonstrate that MTH1 employs an intricate yet promiscuous mechanism of substrate anchoring through its Asp-Asp pharmacophore. The structures suggest that water-mediated interactions convey selectivity towards oxidized substrates over their non-oxidised counterparts, in particular by stabilization of a water molecule in a hydrophobic environment through hydrogen bonding. These findings may be useful in the design of inhibitors of MTH1.


  • Open Access

    Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival

    by Jason G. Kettle, Husam Alwan, Michal Bista, Jason Breed, Nichola L. Davies, Kay Eckersley, Shaun Fillery, Kevin M. Foote, Louise Goodwin, David R. Jones, et al.

    Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the “housekeeping” enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA. We have developed orthogonal and chemically distinct tool compounds to those published in the literature to allow us to test the hypothesis that inhibition of MTH1 has wide applicability in the treatment of cancer. Here we present the work that led to the discovery of three structurally different series of MTH1 inhibitors with excellent potency, selectivity, and proven target engagement in cells. None of these compounds elicited the reported cellular phenotype, and additional siRNA and CRISPR experiments further support these observations. Critically, the difference between the responses of our highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects. As a result, we conclude that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established.